Key result
Sodium-glucose cotransporter-2 inhibitors currently have insufficient evidence regarding their clinical benefits in adults with heart failure with preserved ejection fraction.
Why the study?
While SGLT2 inhibitors improve survival in heart failure with reduced ejection fraction, clinical outcomes in adults with HFpEF had not been systematically reviewed.
Does sodium-glucose cotransporter-2 (SGLT2) inhibitors improve clinical outcomes in adults with heart failure with preserved ejection fraction (HFpEF)?
Does sodium-glucose cotransporter-2 (SGLT2) inhibitors improve clinical outcomes in adults with heart failure with preserved ejection fraction (HFpEF)?
There is currently insufficient evidence to confirm the clinical benefits of SGLT2 inhibitors in patients with heart failure with preserved ejection fraction.
Insufficient evidence advises against routine SGLT2i use in HFpEF; leaves open need for dedicated outcome trials.
Aim: Sodium-glucose cotransporter-2 (SGLT2)-inhibitors improve survival in adults with reduced ejection fraction. Clinical outcomes in adults with heart failure (HF) with preserved ejection fraction (HFpEF) have not been systematically reviewed.
No takes yet. Share an insight, caveat, or question.
Shamliyan et al. (2020) studied this question. Sodium-glucose cotransporter-2 inhibitors currently have insufficient evidence regarding their clinical benefits in adults with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: